NCT04939649View on ClinicalTrials.gov

Ketamine As an Adjunctive Therapy for Major Depression (2)

PHASE3CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

April 18, 2024

Study Completion Date

August 12, 2024

Conditions
Major Depressive EpisodeUnipolar DepressionBipolar Depression
Interventions
DRUG

Ketamine

A sub-anaesthetic dose of ketamine will be administered for up to a four-week course of twice-weekly infusions.

DRUG

Midazolam

A sub-anaesthetic dose of midazolam will be administered for up to a four-week course of twice-weekly infusions.

Trial Locations (1)

D8

St Patrick's Univeristy Hospital, Dublin

All Listed Sponsors
lead

University of Dublin, Trinity College

OTHER

NCT04939649 - Ketamine As an Adjunctive Therapy for Major Depression (2) | Biotech Hunter | Biotech Hunter